Mizuho analyst Mara Goldstein downgraded Forty Seven (FTSV) to Neutral from Buy with a price target of $95.50, up from $53. As the company's bidding process was said to be competitive, a competing takeover to challenge the one from Gilead Sciences (GILD) is unlikely, Goldstein tells investors in a research note. The analyst downgraded Forty Seven to reflect the proposed takeout price.
Brooklyn ImmunoTherapeutics (BTX) announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma, a subsidiary of Gilead Sciences (GILD).